Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.

Park S, Choi H, Kim HJ, Ahn JS, Kim HJ, Kim SH, Mun YC, Jung CW, Kim DDH.

Ann Hematol. 2018 Jun;97(6):955-965. doi: 10.1007/s00277-018-3260-6. Epub 2018 Mar 2.

PMID:
29500710
2.

A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.

Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, Min WS, Kim DH; AML/MDS working party, Korean Society of Hematology.

Am J Hematol. 2012 Oct;87(10):961-8. doi: 10.1002/ajh.23281. Epub 2012 Aug 7.

3.

Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype.

Choi H, Jung C, Sohn SK, Kim S, Kim HJ, Kim YK, Kim T, Zhang Z, Shin ES, Lee JE, Moon JH, Kim SH, Kim KH, Mun YC, Kim H, Park J, Kim J, Kim D.

Br J Haematol. 2013 Oct;163(1):62-71. doi: 10.1111/bjh.12492.

PMID:
24159609
4.

Core binding factor acute myeloid leukaemia and c-KIT mutations.

Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A.

Oncol Rep. 2013 May;29(5):1867-72. doi: 10.3892/or.2013.2328. Epub 2013 Mar 5.

5.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. Epub 2015 Nov 10.

6.

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, Wang Y, Liu YR, Lai YY, Shi HX, Jiang B, Huang XJ.

Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6.

PMID:
25449688
7.

Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.

Park SH, Lee HJ, Kim IS, Kang JE, Lee EY, Kim HJ, Kim YK, Won JH, Bang SM, Kim H, Song MK, Chung JS, Shin HJ.

Ann Lab Med. 2015 May;35(3):288-97. doi: 10.3343/alm.2015.35.3.288. Epub 2015 Apr 1.

8.

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Erratum in: Ann Hematol. 2016 Jan;95(2):363.

PMID:
26537612
9.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

10.

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.

Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY.

Blood Cancer J. 2016 Jul 8;6(7):e442. doi: 10.1038/bcj.2016.51.

11.

KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.

Chen X, Dou H, Wang X, Huang Y, Lu L, Bin J, Su Y, Zou L, Yu J, Bao L.

Leuk Lymphoma. 2018 Apr;59(4):829-836. doi: 10.1080/10428194.2017.1361025. Epub 2017 Aug 9.

PMID:
28792268
12.

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.

J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.

PMID:
26424692
13.

[Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].

Qiao M, Li WY, Sun AN, Chen SN, Liang JY, Ding ZX, Feng YF, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):679-83. Chinese.

PMID:
22339826
14.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

15.

Different prognostic effects of core-binding factor positive AML with Korean AML registry data.

Shin HJ, Min WS, Min YH, Cheong JW, Lee JH, Kim IH, Hong DS, Ahn JS, Kim HJ, Lee WS, Jung CW, Jang JH, Park Y, Kim HJ; Korean Society of Hematology AML/MDS Working Party.

Ann Hematol. 2019 May;98(5):1135-1147. doi: 10.1007/s00277-019-03624-y. Epub 2019 Feb 13.

PMID:
30758645
16.

BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH.

Eur J Haematol. 2013 Aug;91(2):112-21. doi: 10.1111/ejh.12142. Epub 2013 Jun 28.

PMID:
23672350
17.

Integrative analysis of prognostic factors in Chinese core binding factor leukemia.

Wang D, Qiao C, Xiao M, Geng Z, Shang Z, He J, Huang M, Yang Y, Zhang N, Liu Y, Li J, Li C, Zhou J.

Biochem Biophys Res Commun. 2012 Nov 23;428(3):411-5. doi: 10.1016/j.bbrc.2012.10.069. Epub 2012 Oct 26.

PMID:
23107788
18.

XRCC3 Thr241Met polymorphism and risk of acute myeloid leukemia in a Romanian population.

Bănescu C, Tilinca M, Benedek EL, Demian S, Macarie I, Duicu C, Dobreanu M.

Gene. 2013 Sep 10;526(2):478-83. doi: 10.1016/j.gene.2013.05.054. Epub 2013 Jun 4.

PMID:
23747401
19.

[Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].

Li W, Mi YC, Liu BC, Zhou CL, Lin D, Wang HJ, Liu XP, Li QH, Bian SG, Wang JX.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Oct;33(5):517-24. Chinese.

20.

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.

Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10.

PMID:
19520430

Supplemental Content

Support Center